Two years on TRT: what the data says about long-term testosterone therapy

What did @oliandalicia8 actually say?

Over two years on TRT, this creator tracked their testosterone from a baseline low, up to a peak of 35.3 nmol/L (roughly 1,017 ng/dL) in August 2024, then back down to 23.4 nmol/L (674 ng/dL) by June 2025 after their doctor adjusted the dose. They described the August peak as "a little bit above the standard reference range" and said their clinic reduced their dosage in response. They also briefly mentioned estrogen levels at the end, though that section wasn't included in the transcript. The framing is personal, not prescriptive, and the creator consistently attributes dosage decisions to their clinic rather than DIY experimentation.

The units they use, nmol/L and ng/dL, are both legitimate. Their conversion math is roughly correct: 1 nmol/L equals approximately 28.8 ng/dL, so 23.4 nmol/L converts to about 674 ng/dL, which checks out.

Does the science back this up?

Yes, for the most part. The trajectory described here, starting low, titrating upward, peaking above range, and dialing back down, is textbook responsible TRT management. Clinical guidelines from the Endocrine Society (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) recommend targeting mid-normal physiologic range, roughly 400-700 ng/dL, which is exactly where this person landed after dose reduction.

The claim that reaching 677 ng/dL put them "comfortably into the healthy range" is accurate. The standard male reference range in most labs runs from roughly 300-1,000 ng/dL, though the Endocrine Society's treatment target is more conservative. Their peak of 1,017 ng/dL is technically still within some labs' upper reference limits, but it warrants monitoring for side effects including erythrocytosis and cardiovascular strain. Research by Jones et al. (2013, European Journal of Endocrinology) found elevated hematocrit is one of the more common adverse effects when testosterone exceeds physiologic ranges for sustained periods.

What did they get wrong (or right)?

They got the unit conversion right, the clinical reasoning right, and the self-monitoring message right. Credit where it is due. Describing a supratherapeutic level as something to "carefully monitor with your clinic" rather than celebrating it is the responsible call, and it is not what most TRT content on TikTok sounds like.

One area worth pushing back on: the claim that they "could start to feel the difference in energy and focus" at 478 ng/dL after previously being in a low range is plausible, but the symptom timeline deserves some skepticism. Placebo response in hormone therapy is well-documented. Brock et al. (2004, Journal of Urology) found that subjective symptom improvement often precedes any measurable physiologic change in TRT trials. That does not mean the improvement was not real, but attributing it specifically to testosterone at that early stage is hard to verify.

They also never stated their baseline level. Without knowing where they started, phrases like "more than doubled" are impossible to fully evaluate. That is a notable gap in an otherwise data-forward video.

What should you actually know?

TRT is a medical intervention, not a wellness supplement. The Endocrine Society guidelines require a confirmed diagnosis of hypogonadism, based on two fasting morning testosterone measurements below 300 ng/dL plus clinical symptoms, before treatment is indicated. What this creator describes, working with a clinic, adjusting dosage based on blood work, and monitoring levels over time, is how TRT is supposed to work.

What the video does not address matters too. Testosterone therapy suppresses endogenous production through the hypothalamic-pituitary-gonadal axis (Coviello et al., 2004, Journal of Clinical Endocrinology and Metabolism). Stopping TRT without a managed taper can leave someone with lower testosterone than before they started. Long-term cardiovascular data is still evolving; the TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found no increased major cardiac events in hypogonadal men on TRT, but the study population was specific and follow-up had limits.

If you are considering TRT, the unit conversions in this video are accurate, the dose adjustment logic is sound, but one person's two-year arc is not a template for yours.